ID   RPMI-8226-B25
AC   CVCL_E5J8
SY   8226/B25; 8226-B25
RX   DOI=10.1182/blood.V124.21.2084.2084;
CC   Population: African American.
CC   Characteristics: Resistant to 25 nM of bortezomib (DOI=10.1182/blood.V124.21.2084.2084).
CC   Characteristics: Produces IgG lambda (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI_52717; Bortezomib (Velcade).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5722; IGKJ4 + HGNC; HGNC:5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5865; IGLJ3 + HGNC; HGNC:5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0014 ! RPMI-8226
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   DOI=10.1182/blood.V124.21.2084.2084;
RA   Turner J.G., Dawson J.L., Grant S., Shain K.H., Dai Y., Cubitt C.L.,
RA   Baz R.C., Nishihori T., Kauffman M.G., Shacham S., Sullivan D.M.;
RT   "Melphalan and XPO1 inhibitor combination therapy for the treatment of
RT   multiple myeloma.";
RL   Blood 124 Suppl. 1:2084-2084(2014).
//